MX367671B - Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis. - Google Patents
Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis.Info
- Publication number
- MX367671B MX367671B MX2014009464A MX2014009464A MX367671B MX 367671 B MX367671 B MX 367671B MX 2014009464 A MX2014009464 A MX 2014009464A MX 2014009464 A MX2014009464 A MX 2014009464A MX 367671 B MX367671 B MX 367671B
- Authority
- MX
- Mexico
- Prior art keywords
- enuresis
- treatment
- pharmaceutical composition
- composition
- urinary incontinence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3486—Humulus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201230242A ES2423254B1 (es) | 2012-02-15 | 2012-02-15 | Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis |
| PCT/ES2013/070022 WO2013121061A1 (es) | 2012-02-15 | 2013-01-22 | Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014009464A MX2014009464A (es) | 2014-11-12 |
| MX367671B true MX367671B (es) | 2019-08-30 |
Family
ID=48983578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014009464A MX367671B (es) | 2012-02-15 | 2013-01-22 | Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9272011B2 (enExample) |
| EP (1) | EP2815755A4 (enExample) |
| JP (1) | JP6203761B2 (enExample) |
| KR (1) | KR20140127874A (enExample) |
| CN (1) | CN104254338B (enExample) |
| AU (1) | AU2013220284A1 (enExample) |
| BR (1) | BR112014020154A8 (enExample) |
| CA (1) | CA2864426A1 (enExample) |
| CL (1) | CL2014002128A1 (enExample) |
| CO (1) | CO7141408A2 (enExample) |
| CR (1) | CR20140419A (enExample) |
| EA (1) | EA028184B1 (enExample) |
| ES (1) | ES2423254B1 (enExample) |
| IL (1) | IL233978A0 (enExample) |
| MA (1) | MA37324A1 (enExample) |
| MX (1) | MX367671B (enExample) |
| PE (1) | PE20142324A1 (enExample) |
| PH (1) | PH12014501823A1 (enExample) |
| WO (1) | WO2013121061A1 (enExample) |
| ZA (1) | ZA201406668B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110339316B (zh) * | 2019-08-09 | 2021-09-21 | 河南中医药大学 | 一种治疗中风后尿失禁的中药 |
| CN116036153B (zh) * | 2023-02-22 | 2023-09-26 | 深圳市儿童医院 | 啤酒花提取物在制备用于治疗或者预防抑郁症、抑郁症并发症、焦虑症的产品中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| AU677008B2 (en) | 1992-05-20 | 1997-04-10 | Northwestern University | Gaba and L-glutamic acid analogs for antiseizure treatment |
| AU779262B2 (en) * | 1999-04-08 | 2005-01-13 | Warner-Lambert Company | Method for the treatment of incontinence |
| FR2823672B1 (fr) * | 2001-04-23 | 2004-03-12 | Berkem Sa | Extraits de houblon et leur utilisation dans la preparation d'un medicament ayant des proprietes oestrogenes |
| JP2003088335A (ja) * | 2001-09-14 | 2003-03-25 | Pharmafoods Kenkyusho:Kk | 排尿機能改善用食品組成物及びそれを含有する飲食品 |
| GB0306568D0 (en) * | 2003-03-21 | 2003-04-30 | Unilever Plc | Compositions of natural products and use thereof |
| NZ526350A (en) * | 2003-06-09 | 2004-10-29 | A | Anti-aging compositions comprising an amino acid, vitamin B complex, metal salt and an amino alcohol |
| ZA200601975B (en) * | 2003-09-11 | 2007-05-30 | Xenoport Inc | Treating and/or preventing urinary incontinence using prodrugs of GABA analogs |
| JP4815558B2 (ja) * | 2003-10-09 | 2011-11-16 | パシフィック アロー リミテッド | Ｘａｎｔｈｏｃｅｒａｓｓｏｒｂｉｆｏｌｉａ抽出物を含む組成物、該抽出物から単離された化合物、それらを調製する方法、およびそれらの使用 |
| US20070116839A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith |
| EP1889612A3 (en) * | 2006-07-24 | 2008-03-19 | Jan Kees Piet Bruinstroop | Method for controlling micturition |
| US20090180999A1 (en) * | 2008-01-11 | 2009-07-16 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition |
-
2012
- 2012-02-15 ES ES201230242A patent/ES2423254B1/es active Active
-
2013
- 2013-01-22 JP JP2014557094A patent/JP6203761B2/ja not_active Expired - Fee Related
- 2013-01-22 MA MA37324A patent/MA37324A1/fr unknown
- 2013-01-22 MX MX2014009464A patent/MX367671B/es active IP Right Grant
- 2013-01-22 PE PE2014001275A patent/PE20142324A1/es not_active Application Discontinuation
- 2013-01-22 WO PCT/ES2013/070022 patent/WO2013121061A1/es not_active Ceased
- 2013-01-22 EA EA201491437A patent/EA028184B1/ru not_active IP Right Cessation
- 2013-01-22 KR KR1020147025535A patent/KR20140127874A/ko not_active Withdrawn
- 2013-01-22 EP EP13749059.5A patent/EP2815755A4/en not_active Ceased
- 2013-01-22 AU AU2013220284A patent/AU2013220284A1/en not_active Abandoned
- 2013-01-22 CA CA2864426A patent/CA2864426A1/en not_active Abandoned
- 2013-01-22 US US14/378,380 patent/US9272011B2/en not_active Expired - Fee Related
- 2013-01-22 CN CN201380009507.7A patent/CN104254338B/zh not_active Expired - Fee Related
- 2013-01-22 BR BR112014020154A patent/BR112014020154A8/pt not_active Application Discontinuation
-
2014
- 2014-08-06 IL IL233978A patent/IL233978A0/en unknown
- 2014-08-12 PH PH12014501823A patent/PH12014501823A1/en unknown
- 2014-08-12 CL CL2014002128A patent/CL2014002128A1/es unknown
- 2014-09-10 CO CO14200440A patent/CO7141408A2/es unknown
- 2014-09-11 ZA ZA2014/06668A patent/ZA201406668B/en unknown
- 2014-09-12 CR CR20140419A patent/CR20140419A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL233978A0 (en) | 2014-09-30 |
| EP2815755A1 (en) | 2014-12-24 |
| WO2013121061A1 (es) | 2013-08-22 |
| CO7141408A2 (es) | 2014-12-12 |
| CN104254338B (zh) | 2019-05-31 |
| CN104254338A (zh) | 2014-12-31 |
| ES2423254A1 (es) | 2013-09-18 |
| CL2014002128A1 (es) | 2015-03-13 |
| US20150044308A1 (en) | 2015-02-12 |
| EA201491437A1 (ru) | 2015-06-30 |
| EP2815755A4 (en) | 2015-08-05 |
| BR112014020154A2 (enExample) | 2017-06-20 |
| MA37324A1 (fr) | 2016-03-31 |
| US9272011B2 (en) | 2016-03-01 |
| EA028184B1 (ru) | 2017-10-31 |
| JP6203761B2 (ja) | 2017-09-27 |
| PE20142324A1 (es) | 2015-01-16 |
| CR20140419A (es) | 2014-11-28 |
| KR20140127874A (ko) | 2014-11-04 |
| AU2013220284A1 (en) | 2014-09-25 |
| BR112014020154A8 (pt) | 2017-07-11 |
| ES2423254B1 (es) | 2014-03-26 |
| PH12014501823A1 (en) | 2014-11-24 |
| JP2015507002A (ja) | 2015-03-05 |
| ZA201406668B (en) | 2016-05-25 |
| MX2014009464A (es) | 2014-11-12 |
| CA2864426A1 (en) | 2013-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| UY32497A (es) | "2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso" | |
| MX367097B (es) | FORMULACION PARA ANTICUERPO ANTI-A4ß7. | |
| DOP2012000299A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| ECSP13012473A (es) | Forma de dosificación resistente a alteración que comprende un polímero aniónico | |
| SV2010003581A (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso | |
| ECSP11011456A (es) | Inhibidores de la replicación viral novedosos | |
| MX383317B (es) | FORMULACIÓN PARA ANTICUERPO ANTI-A4ß7. | |
| CU24065B1 (es) | Forma de dosificación farmacéutica que comprende nifedipino y un antagonista de angiotensina ii | |
| AR080295A1 (es) | Composiciones para el cuidado bucal y metodos de tratamiento | |
| ECSP088745A (es) | Derivados sustituidos de cromanol y su uso | |
| ES2429422R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
| BR112012015202A2 (pt) | "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes". | |
| MX347927B (es) | Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb. | |
| BRPI1006849B8 (pt) | composição compreendendo extratos lipofílicos de zingiber officinale e echinacea angustifolia e seu uso na preparação de um medicamento para prevenção e tratamento de refluxo esofágico | |
| CL2012002893A1 (es) | Composición de al menos un ingrediente activo de origen vegetal o sintético análogo del mismo, o extracto de origen vegetal que lo contiene, en una solución acuosa, que además comprende lecitina como agente encapsulante; medicamento que la comprende; método para su preparación; y su uso para tratar parasitosis intestinales. | |
| CO7141408A2 (es) | Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis | |
| ECSP12011951A (es) | Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria | |
| AR087878A1 (es) | Extractos de cynara scolymus para el tratamiento de la dislipidemia | |
| WO2011027344A3 (en) | Combination of vitamin e and beta-glycosphingolipids in compositions and methods for preventing and treating hepatic disorders | |
| AR076479A1 (es) | Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i | |
| ES2446494B1 (es) | Aplicación terapéutica de necrostatina-1 en esteatohepatitis | |
| GT200900295A (es) | Composición farmacéutica que comprende la combinación del agente antimicrobiano ciprofloxacino y el agente antioxidante ácido ascórbico para el tratamiento de infecciones urinarias. | |
| CL2012003434A1 (es) | Composicion dermatologica que comprende una combinacion de: 0,1-1% de oxido de cobre; 0,1-1% de oxido de zinc; 0,1-2% de extracto de calendula ( calenduls spp) y entre 0,1-2% de extracto de matico ( buddleja globosa); uso en el tratamiento y prevencion de afecciones en la pie. | |
| TH134923A (th) | องค์ประกอบสำหรับช่องปากซึ่งมีสิ่งสกัด Garcinia mangostana L. และวิธีที่เกี่ยวข้อง |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |